ABSTRACT
The spread of new coronavirus infection (COVID-19) changes specialists’ approaches to patients with chronic diseases, including those with chronic dermatoses. The high risk of COVID-19 complications in patients with psoriasis is connected to the features of disease pathogenesis (such as high activity of proinflammatory cytokines) and used immunosuppressive therapy. Psoriasis affects up to 1% of children in Europe, while 10–20% of them have moderate or severe form of disease. These children may require immunosuppressive treatment, including genetically engineered biological therapy. There is only limited data on adults and children with psoriasis during the COVID-19 pandemic. © 2021 Publishing House of the Union of Pediatricians. All rights reserved.
ABSTRACT
There is crucial question on further therapeutic tactics for the management of such patients (within the severe epidemiological situation caused by the pandemic of new coronavirus SARS-CoV-2) due to widespread application of genetically engineered biologic drugs (GEBD)in management of immune mediated inflammatory diseases. This review sums up current data on the pathogenesis of COVID-19 with the development of acute respiratory distress syndrome associated with cytokine release syndrome (cytokine storm). The effects of GEBD on COVID-19 pathogenesis and their role in management of COVID-19 severe forms of are considered. This review presents the latest guidelines of international associations/consensus and observations of doctors of various specialties on the issue of interruption/continuation of GEBD therapy and with further consequence evaluation in case of interruption of biological therapy.